Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
作者:Thomas F. Durand-Réville、Janelle Comita-Prevoir、Jing Zhang、Xiaoyun Wu、Tricia L. May-Dracka、Jan Antoinette C. Romero、Frank Wu、April Chen、Adam B. Shapiro、Nicole M. Carter、Sarah M. McLeod、Robert A. Giacobbe、Jeroen C. Verheijen、Sushmita D. Lahiri、Michael D. Sacco、Yu Chen、John P. O’Donnell、Alita A. Miller、John P. Mueller、Rubén A. Tommasi
DOI:10.1021/acs.jmedchem.0c00579
日期:2020.11.12
threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inhibitors (BLIs) can be administered in combination with β-lactam antibiotics to negate the action of the β-lactamases, thereby restoring activity of the β-lactam. Newly developed BLIs offer some advantage over
由于对β-内酰胺类抗生素的耐药性迅速提高,多药耐药的革兰氏阴性细菌感染正日益增加的公共卫生威胁。称为β-内酰胺酶的水解酶在很大程度上构成了耐药表型。可以将β-内酰胺酶抑制剂(BLIs)与β-内酰胺类抗生素联合使用,以抵消β-内酰胺酶的作用,从而恢复β-内酰胺的活性。就酶谱而言,新近开发的BLI较旧BLI更具优势,但仅限于静脉内给药。本文报道了一种新型的口服生物可用的二氮杂双环辛烷(DBO)β-内酰胺酶抑制剂。这种新的DBO,ETX1317,包含一个内环碳-碳双键和一个氟乙酸酯活化基团,并具有针对A,C,和D丝氨酸β-内酰胺酶。ETX1317的酯前药ETX0282具有口服生物利用度,目前正在与头孢泊肟肟普罗西汀联用,作为多药耐药和碳青霉烯耐药的口服疗法肠杆菌感染。